| 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 过敏性哮喘定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 2 | | 2.1 市场规模 | 2 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 6 | | 四、发展趋势 | 7 | | 4.1 精准医疗与靶向治疗加速渗透，推动药物研发向细分亚型聚焦 | 7 | | 4.2 吸入制剂国产化突破与智能化升级，重塑生产与用药体验 | 7 | | 4.3 政策驱动与支付改革倒逼行业升级，创新药与高性价比仿制药共存 | 8 | | 4.4 数字化与全渠道融合深化，重构患者服务与产业生态 | 8 | 2026 年过敏性哮喘药物品牌推荐 一、市场背景 1.1 摘要 中国过敏性哮喘新药研发呈现多元态势。在单克隆抗体药物研发上，多个候选药物临 床研究有不同进展，部分进入临床 2 期及以上关键阶段。靶点涵盖 IL-5、TSLP、IL-4R α等多个方向。如康诺亚司普奇拜单抗（IL- ...

2026 年过敏性哮喘药物品牌推荐 精准控哮，长效无忧 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 过敏性哮喘定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 2 | | 2.1 市场规模 | 2 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 6 | | 四、发展趋势 | 7 | | 4.1 精准医疗与靶向治疗加速渗透，推动药物研发向细分亚型聚焦 | 7 | | 4.2 吸入制剂国产化突破与智能化升级，重塑生产与用药体验 | 7 | | 4.3 政策驱动与支付改革倒逼行业升级，创新药与高性价比仿制药共存 | 8 | | 4.4 数字化与全渠道融合深化，重构患者服务与产业生态 | 8 | 2026 年过敏性哮喘药物品牌推荐 一、市场背景 1.1 摘要 中国过敏性哮喘新药研发呈现多元态势。在单克隆抗体药物研发上，多个候选药物临 床研究有不同进展，部分进入临床 2 期及以上关键阶段。靶点涵盖 IL-5、TSLP ...

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug can specifically bind to and inhibit the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] Group 2: Product Forms - Glycopyrrolate is available in various formulations, including injection, inhalation powder, inhalation solution, oral solution, tablets, and a combination inhalation aerosol with Formoterol [1] - Some formulations, such as Glycopyrrolate injection and Glycopyrrolate/Formoterol inhalation aerosol, have been included in the medical insurance directory [1] Group 3: Sales Performance - In 2024, the hospital sales of Glycopyrrolate injection reached 53.5772 million yuan, representing a year-on-year growth of 38.29% [1] - In the first half of 2025, the hospital sales of Glycopyrrolate injection amounted to 37.407 million yuan, showing a significant year-on-year increase of 79.21% [1]